Chronic hepatitis B: a wave of new therapies on the horizon
Explore this paper's citation graph
Summary
A wave of newly identified drug targets, investigational compounds and experimental strategies that are now under clinical evaluation or in preclinical development for chronic HBV infection are reviewed.
- Type
- book
- Published
- 2015-06-22
- Cited by
- 75
- References
- 134
- Access
- Open access
- OpenAlex
- https://openalex.org/W26112647
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:39373343
Keywords
Computer science
References
- A Randomized Controlled Phase IIb Trial of Antigen-Antibody Immunogenic Complex Therapeutic Vaccine in Chronic Hepatitis B Patients
- Treatment of chronic hepatitis B: Evolution over two decades
- PD-1 Blockage Reverses Immune Dysfunction and Hepatitis B Viral Persistence in a Mouse Animal Model
- A multidisciplinary approach to the management of hepatocellular carcinoma.
- Nucleic Acid Polymers Inhibit Duck Hepatitis B Virus Infection In Vitro
- Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults.
- Therapy for hepatitis C--the costs of success.
- Surveillance for hepatocellular carcinoma: can we focus on the mission?
- Programmed death 1 and programmed death ligand 1 expressions in patients with chronic hepatitis B.
- Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor.
- Hepatitis B virus resistance to nucleos(t)ide analogues.
- PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
- Molecular virology of hepatitis B virus for clinicians.
- Synthesis and Biological Evaluation of Triazolo-pyrimidine Derivatives as Novel Inhibitors of Hepatitis B Virus Surface Antigen (HBsAg) Secretion
- Efficient Inhibition of Hepatitis B Virus Infection by Acylated Peptides Derived from the Large Viral Surface Protein
- A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
- The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus.
- Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
- Alpha-Interferon Suppresses Hepadnavirus Transcription by Altering Epigenetic Modification of cccDNA Minichromosomes
- Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein
Cited by
- Hepatitis B Virus Reverse Transcriptase – Target of Current Antiviral Therapy and Future Drug Development
- Application of CRISPR/Cas9 Technology to HBV
- Cancer drugs for hepatitis B treatment: what do we know?
- Targeting hepatitis B virus cccDNA using CRISPR/Cas9.
- Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: Search for the "magic bullet" to kill cccDNA.
- Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent.
- An update on the strategies used for the treatment of chronic hepatitis B in children
- The current treatment situation and definitions of a cure for chronic HBV infection
- Oxethazaine inhibits hepatitis B virus capsid assembly by blocking the cytosolic calcium-signalling pathway.
- New therapies for chronic hepatitis B
- Opt-Out Panel Testing for HIV, Hepatitis B and Hepatitis C in an Urban Emergency Department: A Pilot Study
- Delta hepatitis: new approaches to therapy
- Hepatitis B virus in children: More therapeutic options—but unknown and known unknowns still present
- A historical perspective on the discovery and elucidation of the hepatitis B virus.
- Control and Eradication Strategies of Hepatitis B Virus.
- Nucleic acid polymers: Broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection.
- New horizon for radical cure of chronic hepatitis B virus infection.
- Towards Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities
- New anti-hepatitis B virus drugs under development and evaluation
- Viral reverse transcriptases.